Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on April 25, 2008, regarding events occurring on that date. The report discloses the entry into a material definitive agreement.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed relates to the new consulting agreement:
- Consulting Fee: $15,000 per month.
- Expenses: Reimbursement of reasonable out-of-pocket expenses.
Material Changes
The Company entered into a new consulting services agreement with The Hauer Group, effective April 1, 2008. This agreement replaces a prior arrangement that expired on March 31, 2008. The new contract is set to expire on April 1, 2009, unless extended by mutual agreement.
Management Commentary, Risks, and Related Party Transactions
The agreement involves a related party transaction. Jerome Hauer, a member of the Company's Board of Directors, serves as the Chief Executive Officer of The Hauer Group. Mr. Hauer and his wife are the sole owners of The Hauer Group. The services provided include strategic consulting and domestic and international marketing advice. The filing does not contain forward-looking guidance, outlook, or specific risk factors beyond the standard disclosure of the related party nature of the agreement.
Key Facts for Investor Verification
- Verify the total annual cost of the consulting agreement ($180,000 base fee plus expenses) relative to the Company's overall operating budget.
- Review the Company's Board of Directors minutes or proxy statements for the approval process of this related party transaction.
- Confirm the specific deliverables and performance metrics associated with the strategic consulting and marketing services.
- Check for any other pending or expired agreements with The Hauer Group or Jerome Hauer.